Universal Ibogaine Inc. reported earnings results for the third quarter and nine months ended April 30, 2024. For the third quarter, the company reported sales was CAD 0.53667 million compared to CAD 0.428329 million a year ago. Net loss was CAD 0.862391 million compared to CAD 0.486596 million a year ago.
For the nine months, sales was CAD 1.77 million compared to CAD 0.469596 million a year ago. Net loss was CAD 1.29 million compared to CAD 2.12 million a year ago. Basic loss per share from continuing operations was CAD 0.01 compared to CAD 0.01 a year ago. Diluted loss per share from continuing operations was CAD 0.01 compared to CAD 0.01 a year ago.